About PolpharmaWe are the largest Polish manufacturer of pharmaceuticals and a leader of the Polish pharmaceutical market. We actively operate in the markets of Central and Eastern Europe, the Caucasus and Central Asia.
ResponsibilityBeing the largest Polish pharmaceutical company we want to help people to live a healthy life in a healthy world. Social responsibility is an integral part of the management strategy in our company.
CareerPolpharma's development is possible only thanks to the commitment of our employees as well as the involvement of students and graduates in various business areas.
Polpharma has opened a specialized research and development and production center for highly active active substances (HP API) in Starogard Gdański. This center will enable the production of key substances used in the treatment of oncological diseases, multiple sclerosis and spinal muscular atrophy (SMA). Polpharma is becoming one of the leaders in the production of HP API worldwide.
In August 2024, Ziołolek joined Polpharma in Poland – Polpharma became the majority shareholder of this company. Ziołolek is a company producing OTC drugs, medical devices, dietary supplements, and cosmetics, including emollients for the care of children and infants. Thanks to this transaction, Polpharma will expand its portfolio with high-quality dermatological products, which will complement our offer for patients.
The beginning of the grassroots initiative #DifferentTogether, founded by a group of Polpharma employees. The aim of the project is to support and help each person feel good in their workplace. Currently, this idea focuses on 3 areas: #TogetherForWomen, #TogetherForGenerations, #TogetherForParents.
The launch of a photovoltaic farm in Starogard Gdański and the production of green energy from RES for the needs of the production plant. The implementation of this project contributes to the reduction of the carbon footprint and is an important element of the energy transformation adopted by ZF Polpharma S.A. The installation consists of 24 rows of structures weighing 82,000 kg of steel, which have been divided into 180 tables built on an area of 25,000 square meters.
As part of the API Business Unit’s development strategy, the KiloLab Laboratory was built – a development and production laboratory for active substances. Thanks to the latest technologies, these processes can be carried out down to (-80)°C on a laboratory and pilot scale. This project is another investment that increases the competitiveness and production-development capabilities of the API BU. Besides, it enables production where the operator’s contact with substances of increased activity has been greatly limited.
The merger of the innovative-implementation company Ipochem Sp. z o.o. with Polfa Warsaw S.A. Ipochem specializes in the production of active substances, which are currently supplied to several dozen pharmaceutical companies around the world. In addition to APIs, it produces semi-finished products for further synthesis, which find buyers in Japan, Germany, and Italy, among others.
Polpharma is a partner of the biopharmaceutical start-up Pikralida. It is a biopharmaceutical start-up specializing in the implementation of R&D projects involving therapeutic solutions using innovative small-molecule substances, innovative formulations of complex drugs, as well as modern drug delivery systems.
The inauguration of the project to implement RNA technology in Poland under the title “Limitless future of RNA therapeutics” at the Institute of Bioorganic Chemistry of the Polish Academy of Sciences in Poznan. The research project is being carried out as part of a grant awarded by the Medical Research Agency for the consortium of the ICHB PAN and Polfa Warsaw, which is part of Polpharma.
The launch of the second part of the Polpharma Distribution Center in Błonie. Currently, at this location, there is a warehouse and pharmaceutical wholesaler with a total area of almost 20,000 square meters and over 35,000 pallet spaces.
As of November 1, 2022, Pharmaceutical Plants Polpharma S.A. became the sole shareholder of Lublin Pharmaceutical Plants Polfa S.A. (Polfa Lublin) through the purchase of shares.
The 20th anniversary of the Polpharma Scientific Foundation, whose mission is expressed by the motto: We Help People of Science. The Foundation is an organization that genuinely supports scientists. Between 2001 and 2021, within the competitions organized by the Foundation, 687 research project proposals were submitted, grants were awarded to 78 teams, and several patent applications have already been made. The results of many works are published in important foreign scientific journals. During this time, the value of funds transferred to the activities of the Polpharma Scientific Foundation amounted to nearly 27 million PLN.
The beginning of the advanced and personalized interactive service PolpharmaForYou, where doctors and company representatives can find organized information about all available digital activities of Polpharma. The service is divided into 5 thematic zones: science, entertainment, polpharma.tv, information for the patients, and news.
The completion of the transfer of the drug production process in glass ampoules from Polfa Warsaw to the Pharmaceutical Plants in Starogard Gdanski, with a simultaneous increase in production capacity to 80 million ampoules per year – which represents a doubling of the previous production capabilities in Starogard Gdanski.
Polpharma’s involvement in the creation of the first Polish test for SARS-CoV-2. Thanks to the collaboration of scientists from the Polish Academy of Sciences and Polish companies, including Polpharma, the first Polish genetic test MediPAN-2G+ FAST COVID has hit the market. It is the fastest among those currently used, very sensitive, and created in Poland.
Verification in the field of sustainable purchasing. As the first company in Poland, we have completed the verification process confirming the compliance of our purchasing system with the ISO 20400 Sustainable Procurement standard.
Inauguration of the internal employee program LEONARDO. Leonardo is a social and educational platform in one. It is used to collect all employee ideas in a structured way and allows tracking of their entire evaluation process from the moment the idea is submitted to the potential implementation.
Opening of a new Polpharma production facility at the plant in Sieradz. The investment consists of a facility for the production of non-sterile liquid forms (syrups, suspensions, solutions), a warehouse for packaging materials and raw materials, and a modern R&D laboratory for conducting development work for technologically advanced inhalation drugs.
The first commercial series of the drug manufactured in the new Medana production department, belonging to the Polpharma Group, was released for trading. This way, the company completed a 4-year investment period, which included a new facility for the production of non-sterile liquid forms, a new warehouse of packaging materials and raw materials, and a new R&D laboratory, where development projects in the field of inhalation drugs are carried out.
According to the decision of the Supervisory Board of Polpharma S.A., the process of separating the Biotechnology Department from the Pharmaceutical Works Polpharma S.A. was completed. As a result, Polpharma Biologics became an independent legal entity.
Polpharma took first place in the XII Ranking of Responsible Companies – the most important list of leaders of social responsibility and sustainable development in Poland. For the first time in the history of the ranking, a Polish company has won the leadership position. Polpharma obtained the maximum possible number of points. The company would repeat this success in 2019.
A new investment was launched in Sieradz: construction of the new Non-Sterile Fluid Plant increased the production capacity of current drugs and enabled the introduction of further products from the portfolio of both Medana Pharma S.A. as well as other companies in Polpharma Group.
Polpharma celebrated its 80th anniversary. To mark this occasion, it organised the Polrun relay race.
Polpharma published the first CSR report according to the Global Reporting Initiative (GRI) guidelines.
Polpharma started a strategic joint venture cooperation in the area of biotechnology with the German company Neuraxpharm.
The company Sanfarm, based in the Tarnobrzeg Special Economic Zone, became part of Polpharma S.A. Pharmaceutical Works. Following the merger of the two companies, Polpharma’s Manufacturing Division in Nowa Dęba was established to carry out pharmaceutical manufacturing operations for both member companies of Polpharma Group and third parties.
Polpharma passed an inspection by the Food and Drug Administration (FDA). As a result, APIs manufactured by the company gained access to the highly developed US market.
Polpharma received ISO 14001 environmental certificate and an OHSAS 18001 occupational health and safety certificate.
Polpharma began strategic cooperation with Akrikhin – one of the largest pharmaceutical companies in Russia.
Polpharma established an independent affiliated company in Belarus. Previously, the division in Lithuania was responsible for this country.
Polpharma opened a new training and administration centre in Starogard Gdański, which significantly expanded the company’s capabilities relating to the organisation of training sessions and meetings with clients and guests.
The company started operation of a new ampoule production facility. Its annual production capacity amounts to 50 million glass ampoules. The property was designed and built in accordance with cGMP requirements for sterile production.
The company opened another facility – a Logistics Centre. The building complies with the requirements of Good Distribution Practice (GDP) for the storage of pharmaceutical products.
Polpharma opened a modern building for the Research and Development Centre and Quality Control Laboratory. The facility meets the requirements of Good Laboratory Practice (GLP). It is one of the largest facilities of its kind in Central and Eastern Europe.
Polpharma implemented a coherent and modern visual identification for packages of prescription drugs.
Polscreen, a National Coronary Heart Disease Prevention Program, began. It was the largest global population-based study, developed by the Prevention Committee of the Polish Cardiac Society, financed by a research grant for Polpharma and awarded funds for the years 2002–2005.
A Trade Office was established in Warsaw, with dynamic and modern marketing and sales structures. The Office is located at ul. Sapieżyńska.
The first Etopiryna commercial appeared on TV. Since that time, this drug for headache has inevitably been associated with Ms Goździkowa, a well-known commercial actress.
Polpharma established the Foundation for the Development of Polish Pharmacy and Medicine, which annually announces a competition for the best research projects.
The company opened a division in Moscow operating in the Russian Federation and the Central Asian republics. It also established a branch in Ukraine.
A new chapter in Polpharma history opened on 20 July. The company became a privately-owned entity, with all its shares held by Polish investors. The Spectra Management and Prokom Investments Consortium became the majority shareholder of the Company. This was the beginning of restructuring and significant investment in the development of the company.
Polpharma began the construction of a new solid dosage forms manufacturing facility. The facility, built through the cooperation of an international team, was one of the most modern pharmaceutical plants in Europe.
The company starts business operation as a sole-shareholder company owned by the State Treasury, and returns to the historic name “Polpharma”.
The company exceeded 3000 employees. Exports of pharmaceutical substances and medicines represented approximately 50% of the company’s sales. The products of Starogard-based “Polfa” were sold to 60 countries on all continents.
The production of pharmaceutical substances grew, followed by the production of finished dosage forms: tablets and ampoules.
Polpharma was nationalised. Two chemists – Zygmunt Gmaj and Jerzy Sumczyński – become the managers of the facility.
